ISRCTN86755640 https://doi.org/10.1186/ISRCTN86755640

Does furosemide improve renal function in patients stopping renal replacement therapy?

Submission date	Recruitment status	[_] Prospectively registered
30/09/2004	No longer recruiting	[_] Protocol
Registration date	**Overall study status**	[_] Statistical analysis plan
30/09/2004	Completed	[_] Results
Last Edited	**Condition category**	[_] Individual participant data
02/02/2017	Urological and Genital Diseases	[_] Record updated in last year

Plain English summary of protocol
Not provided at time of registration

Contact information

Type(s)
Scientific

Contact name
Dr Neil Soni

Contact details
Magill Dept of Anaesthetics, 3rd Floor, D Lift
Chelsea & Westminster Hospital
369 Fulham Road
London
United Kingdom
SW10 9NH
+44 (0)20 8237 2763
n.soni@imperial.ac.uk

Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers
N0060110642

Study information

Scientific Title
Does furosemide improve renal function in patients stopping renal replacement therapy?

Study objectives
Does furosemide improve renal function in patients stopping renal replacement therapy?

Ethics approval required
Old ethics approval format

Ethics approval(s)
Not provided at time of registration

Study design
Randomised controlled trial parallel design

Primary study design
Interventional

Secondary study design
Randomised controlled trial

Study setting(s)
Hospital

Study type(s)
Treatment

Participant information sheet
Not available in web format, please use contact details to request a participant information sheet

Health condition(s) or problem(s) studied
Urological and Genital Diseases: Renal function

Interventions
Furosemide vs no furosemide

Intervention Type
Drug

Phase
Not Applicable

Drug/device/biological/vaccine name(s)
Furosemide

Primary outcome measure
Change in creatinine clearance after 24 hours of receiving, or not, furosemide infusion

Secondary outcome measures
Other outcome measures include rate of resumption of renal replacement therapy, peak creatinine, requirement for mineral replacement

Overall study start date
11/02/2002

Completion date
31/07/2007

Eligibility

Key inclusion criteria
50 patients. 1 per week.

Participant type(s)
Patient

Age group
Not Specified

Sex
Not Specified

Target number of participants
50

Key exclusion criteria
Not provided at time of registration

Date of first enrolment
11/02/2002

Date of final enrolment
31/07/2007

Locations

Countries of recruitment
England

United Kingdom

Study participating centre

Chelsea & Westminster Hospital
London
United Kingdom
SW10 9NH

Sponsor information

Organisation
Department of Health

Sponsor details
Richmond House
79 Whitehall
London
United Kingdom
SW1A 2NL

Sponsor type
Government

Website
http://www.dh.gov.uk/Home/fs/en

Funder(s)

Funder type
Hospital/treatment centre

Funder Name
Chelsea and Westminster Healthcare NHS Trust (UK)

Results and Publications

Publication and dissemination plan
Not provided at time of registration

Intention to publish date

Individual participant data (IPD) sharing plan

IPD sharing plan summary

Not provided at time of registration